Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $AMRX vs $ELVN | Chartloom

Compare

$AMRX vs $ELVN

Amneal Pharmaceuticals Inc · Enliven Therapeutics Inc

AMRX

Amneal Pharmaceuticals Inc

ELVN

Enliven Therapeutics Inc

Compare $AMRX vs $ELVN

Comparing Amneal Pharmaceuticals Inc and Enliven Therapeutics Inc

AMRXAmneal Pharmaceuticals Inc

ELVNEnliven Therapeutics Inc

AMRXAmneal Pharmaceuticals Inc

Market cap

$6.25B

P/E (TTM)

40.80x

Forward P/E (NTM)

19.08x

Forward P/S (NTM)

1.89x

Rev growth (TTM)

9.3%

YTD performance

54.6%

52W performance

96.3%

FCF yield

-0.2%

ELVNEnliven Therapeutics Inc

Market cap

$2.76B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

154.1%

52W performance

89.7%

FCF yield

-2.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AMRX

ELVN

Detailed metrics comparison

AMRX

Amneal Pharmaceuticals Inc

ELVN

Enliven Therapeutics Inc

Market Cap

AMRX$6.25B

ELVN$2.76B

Enterprise Value

AMRX$8.85B

ELVN$2.62B

Price

AMRX$19.57

ELVN$39.49

P/E Ratio

AMRX40.80x

ELVNN/A

P/S Ratio

AMRX2.00x

ELVN0.00x

EV/Sales

AMRX2.84x

ELVN0.00x

EV/EBITDA

AMRX13.14x

ELVN770.73x

P/B Ratio

AMRX192.54x

ELVN3.35x

P/FCF Ratio

AMRXN/A

ELVNN/A

EV/FCF

AMRX-719.11x

ELVN-39.11x

PEG Ratio

AMRX1.98x

ELVNN/A

Forward P/E (NTM)

AMRX19.08x

ELVNN/A

Forward P/S (NTM)

AMRX1.89x

ELVNN/A

Revenue (TTM)

AMRX$3.12B

ELVN$0

Revenue Growth (YoY)

AMRX9.3%

ELVNN/A

Forward Rev Growth

AMRX9.0%

ELVN28.4%

Gross Margin (TTM)

AMRX39.3%

ELVN0.0%

Operating Margin (TTM)

AMRX14.6%

ELVN0.0%

EBITDA Margin (TTM)

AMRX21.6%

ELVN0.0%

Net Margin (TTM)

AMRX5.0%

ELVN0.0%

FCF Margin (TTM)

AMRX-0.4%

ELVNN/A

Net Income (TTM)

AMRX$157M

ELVN$-106M

FCF (TTM)

AMRX$-12M

ELVN$-67M

EPS (TTM)

AMRX$0.48

ELVN-$1.60

ROE (TTM)

AMRX174.6%

ELVN-1855.0%

ROA (TTM)

AMRX4.3%

ELVN-1809.0%

ROIC (TTM)

AMRX2.1%

ELVN-1855.0%

Cash

AMRX$128M

ELVN$136M

Debt

AMRX$2.73B

ELVN$0

Net Cash/Debt

AMRX$-2.60B

ELVN$136M

Current Ratio (TTM)

AMRX2.20x

ELVN64.07x

Quick Ratio (TTM)

AMRX1.38x

ELVN63.21x

Debt/Equity (TTM)

AMRX82.62x

ELVN0.00x

Debt/Assets (TTM)

AMRX0.0%

ELVN0.0%

Interest Coverage (TTM)

AMRXN/A

ELVNN/A

Net Debt/EBITDA (TTM)

AMRX0.00x

ELVN0.00x

Beta

AMRX1.22

ELVN0.55

52W Performance

AMRX96.3%

ELVN89.7%

YTD Performance

AMRX54.6%

ELVN154.1%

% from 52W High

AMRX-7.6%

ELVN-36.6%

% from 52W Low

AMRX104.7%

ELVN167.1%

Asset Turnover (TTM)

AMRX0.85x

ELVN0.00x

FCF Yield (TTM)

AMRX-0.2%

ELVN-2.4%

Earnings Yield (TTM)

AMRX2.5%

ELVN-3.8%

Dividend Yield (TTM)

AMRXN/A

ELVNN/A

Rule of 40

AMRX8.9

ELVN0.0

EV/GP/RG

AMRX1.16

ELVNN/A

Ticker research

View AMRX research View ELVN research

Metric	AMRX Amneal Pharmaceuticals Inc	ELVN Enliven Therapeutics Inc
Market & Valuation
Market Cap	$6.25B	$2.76B
Enterprise Value	$8.85B	$2.62B
Price	$19.57	$39.49
P/E Ratio	40.80x	N/A
P/S Ratio	2.00x	0.00x
EV/Sales	2.84x	0.00x
EV/EBITDA	13.14x	770.73x
P/B Ratio	192.54x	3.35x
P/FCF Ratio	N/A	N/A
EV/FCF	-719.11x	-39.11x
PEG Ratio	1.98x	N/A
Forward P/E (NTM)	19.08x	N/A
Forward P/S (NTM)	1.89x	N/A
Revenue & Growth
Revenue (TTM)	$3.12B	$0
Revenue Growth (YoY)	9.3%	N/A
Forward Rev Growth	9.0%	28.4%
Profitability
Gross Margin (TTM)	39.3%	0.0%
Operating Margin (TTM)	14.6%	0.0%
EBITDA Margin (TTM)	21.6%	0.0%
Net Margin (TTM)	5.0%	0.0%
FCF Margin (TTM)	-0.4%	N/A
Net Income (TTM)	$157M	$-106M
FCF (TTM)	$-12M	$-67M
EPS (TTM)	$0.48	-$1.60
ROE (TTM)	174.6%	-1855.0%
ROA (TTM)	4.3%	-1809.0%
ROIC (TTM)	2.1%	-1855.0%
Financial Health
Cash	$128M	$136M
Debt	$2.73B	$0
Net Cash/Debt	$-2.60B	$136M
Current Ratio (TTM)	2.20x	64.07x
Quick Ratio (TTM)	1.38x	63.21x
Debt/Equity (TTM)	82.62x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.22	0.55
52W Performance	96.3%	89.7%
YTD Performance	54.6%	154.1%
% from 52W High	-7.6%	-36.6%
% from 52W Low	104.7%	167.1%
Efficiency & Yields
Asset Turnover (TTM)	0.85x	0.00x
FCF Yield (TTM)	-0.2%	-2.4%
Earnings Yield (TTM)	2.5%	-3.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	8.9	0.0
EV/GP/RG	1.16	N/A
Ticker research	View AMRX research	View ELVN research

Valuation

P/E Ratio

AMRX

40.80x

P/S Ratio

ELVN

0.00x

AMRX

2.00x

EV/FCF

AMRX

-719.11x

ELVN

-39.11x

Growth & revenue

Revenue Growth TTM

AMRX

9.3%

Forward Revenue Growth

ELVN

28.4%

AMRX

9.0%

Profitability & performance

Gross Margin

AMRX

39.3%

ELVN

0.0%

ROE

AMRX

174.6%

ELVN

-1855.0%

FCF Yield %

AMRX

-0.2%

ELVN

-2.4%

52-Week Performance

AMRX

96.3%

ELVN

89.7%

Detailed metrics comparison

AMRX

Amneal Pharmaceuticals Inc

ELVN

Enliven Therapeutics Inc

Market Cap

AMRX$6.25B

ELVN$2.76B

Enterprise Value

AMRX$8.85B

ELVN$2.62B

Price

AMRX$19.57

ELVN$39.49

P/E Ratio

AMRX40.80x

ELVNN/A

P/S Ratio

AMRX2.00x

ELVN0.00x

EV/Sales

AMRX2.84x

ELVN0.00x

EV/EBITDA

AMRX13.14x

ELVN770.73x

P/B Ratio

AMRX192.54x

ELVN3.35x

P/FCF Ratio

AMRXN/A

ELVNN/A

EV/FCF

AMRX-719.11x

ELVN-39.11x

PEG Ratio

AMRX1.98x

ELVNN/A

Forward P/E (NTM)

AMRX19.08x

ELVNN/A

Forward P/S (NTM)

AMRX1.89x

ELVNN/A

Revenue (TTM)

AMRX$3.12B

ELVN$0

Revenue Growth (YoY)

AMRX9.3%

ELVNN/A

Forward Rev Growth

AMRX9.0%

ELVN28.4%

Gross Margin (TTM)

AMRX39.3%

ELVN0.0%

Operating Margin (TTM)

AMRX14.6%

ELVN0.0%

EBITDA Margin (TTM)

AMRX21.6%

ELVN0.0%

Net Margin (TTM)

AMRX5.0%

ELVN0.0%

FCF Margin (TTM)

AMRX-0.4%

ELVNN/A

Net Income (TTM)

AMRX$157M

ELVN$-106M

FCF (TTM)

AMRX$-12M

ELVN$-67M

EPS (TTM)

AMRX$0.48

ELVN-$1.60

ROE (TTM)

AMRX174.6%

ELVN-1855.0%

ROA (TTM)

AMRX4.3%

ELVN-1809.0%

ROIC (TTM)

AMRX2.1%

ELVN-1855.0%

Cash

AMRX$128M

ELVN$136M

Debt

AMRX$2.73B

ELVN$0

Net Cash/Debt

AMRX$-2.60B

ELVN$136M

Current Ratio (TTM)

AMRX2.20x

ELVN64.07x

Quick Ratio (TTM)

AMRX1.38x

ELVN63.21x

Debt/Equity (TTM)

AMRX82.62x

ELVN0.00x

Debt/Assets (TTM)

AMRX0.0%

ELVN0.0%

Interest Coverage (TTM)

AMRXN/A

ELVNN/A

Net Debt/EBITDA (TTM)

AMRX0.00x

ELVN0.00x

Beta

AMRX1.22

ELVN0.55

52W Performance

AMRX96.3%

ELVN89.7%

YTD Performance

AMRX54.6%

ELVN154.1%

% from 52W High

AMRX-7.6%

ELVN-36.6%

% from 52W Low

AMRX104.7%

ELVN167.1%

Asset Turnover (TTM)

AMRX0.85x

ELVN0.00x

FCF Yield (TTM)

AMRX-0.2%

ELVN-2.4%

Earnings Yield (TTM)

AMRX2.5%

ELVN-3.8%

Dividend Yield (TTM)

AMRXN/A

ELVNN/A

Rule of 40

AMRX8.9

ELVN0.0

EV/GP/RG

AMRX1.16

ELVNN/A

Ticker research

View AMRX research View ELVN research

Metric	AMRX Amneal Pharmaceuticals Inc	ELVN Enliven Therapeutics Inc
Market & Valuation
Market Cap	$6.25B	$2.76B
Enterprise Value	$8.85B	$2.62B
Price	$19.57	$39.49
P/E Ratio	40.80x	N/A
P/S Ratio	2.00x	0.00x
EV/Sales	2.84x	0.00x
EV/EBITDA	13.14x	770.73x
P/B Ratio	192.54x	3.35x
P/FCF Ratio	N/A	N/A
EV/FCF	-719.11x	-39.11x
PEG Ratio	1.98x	N/A
Forward P/E (NTM)	19.08x	N/A
Forward P/S (NTM)	1.89x	N/A
Revenue & Growth
Revenue (TTM)	$3.12B	$0
Revenue Growth (YoY)	9.3%	N/A
Forward Rev Growth	9.0%	28.4%
Profitability
Gross Margin (TTM)	39.3%	0.0%
Operating Margin (TTM)	14.6%	0.0%
EBITDA Margin (TTM)	21.6%	0.0%
Net Margin (TTM)	5.0%	0.0%
FCF Margin (TTM)	-0.4%	N/A
Net Income (TTM)	$157M	$-106M
FCF (TTM)	$-12M	$-67M
EPS (TTM)	$0.48	-$1.60
ROE (TTM)	174.6%	-1855.0%
ROA (TTM)	4.3%	-1809.0%
ROIC (TTM)	2.1%	-1855.0%
Financial Health
Cash	$128M	$136M
Debt	$2.73B	$0
Net Cash/Debt	$-2.60B	$136M
Current Ratio (TTM)	2.20x	64.07x
Quick Ratio (TTM)	1.38x	63.21x
Debt/Equity (TTM)	82.62x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.22	0.55
52W Performance	96.3%	89.7%
YTD Performance	54.6%	154.1%
% from 52W High	-7.6%	-36.6%
% from 52W Low	104.7%	167.1%
Efficiency & Yields
Asset Turnover (TTM)	0.85x	0.00x
FCF Yield (TTM)	-0.2%	-2.4%
Earnings Yield (TTM)	2.5%	-3.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	8.9	0.0
EV/GP/RG	1.16	N/A
Ticker research	View AMRX research	View ELVN research